Promising New Migraine Drug Offers Relief for Difficult Cases
A new study has found that atogepant, a recently approved preventative migraine drug, can help even the most difficult cases of migraines. Patients who hadn’t responded to other treatments experienced noticeably fewer days with migraine while on atogepant than those given a placebo. The FDA expanded the drug’s intended use this month, approving it for adults with chronic migraines. Atogepant is part of a relatively new class of migraine drugs called calcitonin gene-related peptide (CGRP) inhibitors. However, the drug comes with a high price tag of upwards of $1,000 a month without insurance.